Document is current
Any future updates will be listed below
-
Authors
Ma, Jing
Sarén, Tina
Jin, Chuan
Kim, Hyeong Su
Contreras Pineda, Paola Donaji
de Bernard, Marina
Amini, Rose-Marie
Rondahl, Veronica
Enblad, Gunilla
Yu, Di
Essand, Magnus
-
Funding
Funding for this research was provided by:
Erik, Karin och Gösta Selanders stiftelse (2023)
Cancerfonden (22-2229Pj, 19-0184Pj)
Barncancerfonden (PR2022-0105, PR2020-0167)
VINNOVA (2021-04488)
Vetenskapsrådet (2019-01326)
Uppsala University
- License Information
-
More Information
Article History
Received: 26 August 2024
Accepted: 6 June 2025
First Online: 12 July 2025
Declarations
:
: DY and ME hold shares in Elicera Therapeutics, a company that develops NAP-armed CAR-T cells. JM, TS, and CJ receive financial compensation from Elicera Therapeutics. The other authors declare no financial conflict of interest.
